Related Experiment Videos
Tyrosinemia type I: a clinico-laboratory case report
Deepali Karnik1, Niranjan Thomas, C E Eapen
1Neurochemistry Laboratory, CMC Hospital, Vellore, India.
Indian Journal of Pediatrics
|November 9, 2004
Summary
Tyrosinemia type Ib, a rare metabolic disorder, is suggested by specific neonatal symptoms including elevated alpha-fetoprotein and amino acid imbalances. This condition stems from a deficiency in maleylacetoacetate isomerase.
Area of Science:
- Biochemistry
- Genetics
- Pediatric Medicine
Background:
- Hereditary tyrosinemia encompasses several genetic disorders affecting amino acid metabolism.
- Tyrosinemia type I is classically linked to fumarylacetoacetate hydrolase deficiency.
- Distinguishing between tyrosinemia subtypes is crucial for accurate diagnosis and management.
Observation:
- A neonate presented with progressive liver dysfunction.
- Key biochemical findings included elevated serum alpha-fetoprotein, hypertyrosinemia, hypermethioninemia, and generalized amino aciduria.
- Notably, urinary delta-aminolevulinic acid and succinylacetone were absent.
Findings:
- The observed clinical and biochemical profile strongly suggests tyrosinemia type Ib.
- This specific subtype results from a deficiency of the enzyme maleylacetoacetate isomerase.
- This contrasts with tyrosinemia type I, caused by fumarylacetoacetate hydrolase deficiency.
Implications:
- Accurate diagnosis of tyrosinemia type Ib is essential for initiating appropriate treatment.
- Early identification can prevent severe complications associated with liver dysfunction.
- Understanding the specific enzyme deficiency guides further research into metabolic pathways and potential therapies.